Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

ABSTRACT:

Background

Cost-effectiveness analyses in patients with migraine require estimates of patients' utility values and how these relate to monthly migraine days (MMDs). This analysis examined four different modelling approaches to assess utility values as a function of MMDs.

Methods

Disease-specific patient-reported outcomes from three erenumab clinical studies (two in episodic migraine [NCT02456740 and NCT02483585] and one in chronic migraine [NCT02066415]) were mapped to the 5-dimension EuroQol questionnaire (EQ-5D) as a function of the Migraine-Specific Quality of Life Questionnaire (MSQ) and the Headache Impact Test (HIT-6™) using published algorithms. The mapped utility values were used to estimate generic, preference-based utility values suitable for use in economic models

SUBMITTER: Di Tanna GL 

PROVIDER: S-EPMC6852901 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature